N-[5-(3-fluoropyridin-4-yl)-6-(1,3-oxazol-5-yl)pyrazin-2-yl]cyclopropanecarboxamide | 1262210-38-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-[5-(3-fluoropyridin-4-yl)-6-(1,3-oxazol-5-yl)pyrazin-2-yl]cyclopropanecarboxamide
• CAS: 1262210-38-7
• 化学式: C₁₆H₁₂FN₅O₂
• 分子量: 325.302
• InChiKey: QRZYIOBBNKOVAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  93.8
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  6-chloro-5-(3-fluoropyridine-4-yl)pyrazine-2-amine 在 吡啶 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 caesium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 生成 N-[5-(3-fluoropyridin-4-yl)-6-(1,3-oxazol-5-yl)pyrazin-2-yl]cyclopropanecarboxamide
  参考文献：
  名称：

  Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A_2B Adenosine Receptor Antagonist

  摘要：

  The structure activity relationships for a series of pyrazine-based A(2B) adenosine receptor antagonists are described. From this work, LAS101057 (17), a potent, selective, and orally efficacious A(2B) receptor antagonist, was identified as a clinical development candidate. LAS101057 inhibits agonist-induced IL-6 production in human fibroblasts and is active in an ovalbumin (OVA)-sensitized mouse model after oral administration, reducing airway hyperresponsiveness to methacholine, Th2 cytokine production, and OVA-specific IgE levels.

  DOI：

  10.1021/ml100249e

文献信息

• Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A_2B Adenosine Receptor Antagonist
  作者：Paul Eastwood、Cristina Esteve、Jacob González、Silvia Fonquerna、Josep Aiguadé、Inés Carranco、Teresa Doménech、Mònica Aparici、Montserrat Miralpeix、Joan Albertí、Mónica Córdoba、Raquel Fernández、Mercè Pont、Núria Godessart、Neus Prats、María Isabel Loza、María Isabel Cadavid、Arsenio Nueda、Bernat Vidal

  DOI：10.1021/ml100249e

  日期：2011.3.10

  The structure activity relationships for a series of pyrazine-based A(2B) adenosine receptor antagonists are described. From this work, LAS101057 (17), a potent, selective, and orally efficacious A(2B) receptor antagonist, was identified as a clinical development candidate. LAS101057 inhibits agonist-induced IL-6 production in human fibroblasts and is active in an ovalbumin (OVA)-sensitized mouse model after oral administration, reducing airway hyperresponsiveness to methacholine, Th2 cytokine production, and OVA-specific IgE levels.